Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chelsea Shafranek

Physician Assistant, Medical Allston, MA Physician Assistant

NPI 1710546411 CMS profile 11254098

66 Chester St Apt 3, Allston, MA 02134

Open in the dashboard

General payments

$4,452

226 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chelsea Shafranek of Allston, MA is reported in the CMS Open Payments database as having received $4,452 across 226 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $400 18
2024 General $1,301 62
2023 General $1,022 52
2022 General $790 42
2021 General $940 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chelsea Shafranek
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Chelsea Shafranek were reported at $400. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Chelsea Shafranek Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $940 $156 $41–$563 $132
2022 $790 $185 $55–$649 $149
2023 $1,022 $199 $58–$717 $160
2024 $1,301 $206 $62–$740 $164
2025 $400 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $990 55 payments
  2. Novo Nordisk Inc $465 24 payments
  3. Lilly USA, LLC $400 19 payments
  4. AstraZeneca Pharmaceuticals LP $341 17 payments
  5. Pfizer Inc. $289 14 payments
  6. Sanofi-Aventis U.S. LLC $212 12 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $174 9 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $166 7 payments
  9. Exact Sciences Corporation $144 7 payments
  10. Merck Sharp & Dohme Corporation $130 6 payments
  11. Other $1,139 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,452 226 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $353 22 payments
  2. LINZESS $296 16 payments
  3. RYBELSUS $257 14 payments
  4. Ozempic $247 14 payments
  5. QULIPTA $242 11 payments
  6. UBRELVY $214 11 payments
  7. SOLIQUA 100/33 $212 12 payments
  8. MOUNJARO $184 8 payments
  9. JARDIANCE $177 9 payments
  10. Kerendia $174 9 payments
  11. Other $3,374 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

513

Median for Physician Assistant: 241

Drug cost

$14,694

Median for Physician Assistant: $4,110

Branded share of claims

25.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 45 $8,545
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 58 $1,162
Lidocaine Generic 12 $962
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $558
Acetaminophen-Codeine Acetaminophen With Codeine Brand 14 $485
Mirtazapine Generic 19 $408
Levothyroxine Sodium Generic 31 $294
Eszopiclone Generic 12 $291
Gabapentin Generic 22 $244
Rosuvastatin Calcium Generic 13 $226

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $145
$145 — —
JARDIANCE
  • Lilly USA, LLC $75
  • Boehringer Ingelheim Pharmaceuticals, Inc. $54
$129 — —
UBRELVY
  • AbbVie, Inc. $76
$76 — —
Wegovy
  • Novo Nordisk Inc $70
$70 — —
REXULTI
  • Lundbeck LLC $43
  • Otsuka America Pharmaceutical, Inc. $24
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record